News

ZymoGenetics has received rights to potential milestones and royalties, in exchange for licensing Seattle Life Sciences (SLS) rights to develop the product candidates. In addition, ZymoGenetics is entitled

The company has recently completed a Phase III clinical trial in the US with its flagship IV Alpha-1 Antitrypsin (AAT) product indicated for treating AAT deficiency and is

The Calix spinal implant system is reportedly designed to function as a cervical intervertebral fixation device as well as a vertebral body replacement device in the thoracic and

The product incorporates Circ Pharma’s drug delivery technology enabling once daily dosing. Circ’s technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption

Australian pharmaceutical company Pharmaxis has reported positive results of its recently completed international Phase III trial of Bronchitol in people with cystic fibrosis. The primary endpoint of the

The patent, issued in Australia, covers Thymosin Beta 4, its analogues, isoforms and other derivatives and expires in 2022. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259

Biovail Laboratories International (BLS) has acquired the US and Canadian rights to develop, manufacture and commercialize pimavanserin tartrate in a number of neurological and psychiatric conditions, including Parkinson’s

Under the agreement, the two companies will develop diagnostic products that incorporate Fujirebio Diagnostics’s cancer biomarkers for use on Becton, Dickinson and Company’s (BD) multiplex testing platform. The

By means of this exclusive licensing-in agreement Almirall will be responsible for the commercialization of linaclotide in all country members of the EU, plus Russia, CIS, Switzerland, Norway